Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolLON:VRP
CUSIPN/A
Phone+44-20-32834200
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-30.13%
Return on Assets-26.97%
Miscellaneous
EmployeesN/A
Outstanding Shares105,020,000
Verona Pharma (LON:VRP) Frequently Asked Questions
What is Verona Pharma's stock symbol?
Verona Pharma trades on the London Stock Exchange (LON) under the ticker symbol "VRP."
How were Verona Pharma's earnings last quarter?
Verona Pharma Plc (LON:VRP) announced its earnings results on Tuesday, May, 8th. The company reported ($14.50) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($23.70) by $9.20. View Verona Pharma's Earnings History.
What price target have analysts set for VRP?
3 Wall Street analysts have issued 1-year target prices for Verona Pharma's shares. Their predictions range from GBX 160 to GBX 348. On average, they anticipate Verona Pharma's stock price to reach GBX 252.67 in the next twelve months. View Analyst Ratings for Verona Pharma.
Who are some of Verona Pharma's key competitors?
Some companies that are related to Verona Pharma include Mesoblast (MEOBF), Emerald Health Therapeutics (EMH), Starpharma (SPL), MediGene (MDG1), Oxford BioMedica (OXB), BioTime (BTX), Resverlogix (RVX), 22nd Century Group (XXII), Protalix Biotherapeutics (PLX), Neptune Technologies & Bioressources (NEPT), Monash IVF Group (MVF), ABcann Global (ABCN), Horizon Discovery Group (HZD), IMV (IMV) and Faron Pharmaceuticals Oy (FARN).
Who are Verona Pharma's key executives?
Verona Pharma's management team includes the folowing people:
- Dr. Jan-Anders Karlsson, Chief Exec. Officer & Exec. Director (Age 63)
- Mr. Piers John Morgan MA, ACA, Chief Financial Officer (Age 52)
- Ms. Claire Louise Poll, Legal Counsel (Age 51)
- Dr. Peter Spargo Ph.D., Sr. VP of CMC (Age 56)
- Dr. Kenneth Newman, Chief Medical Officer (Age 60)
Has Verona Pharma been receiving favorable news coverage?
News stories about VRP stock have trended somewhat positive on Wednesday, Accern Sentiment reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Verona Pharma earned a media sentiment score of 0.08 on Accern's scale. They also assigned media coverage about the company an impact score of 44.59 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
How do I buy shares of Verona Pharma?
Shares of VRP and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Verona Pharma's stock price today?
One share of VRP stock can currently be purchased for approximately GBX 155.
How big of a company is Verona Pharma?
Verona Pharma has a market capitalization of £160.79 million.
How can I contact Verona Pharma?
Verona Pharma's mailing address is 3 More London Riverside, LONDON, SE1 2RE, United Kingdom. The company can be reached via phone at +44-20-32834200.
MarketBeat Community Rating for Verona Pharma (VRP)
MarketBeat's community ratings are surveys of what our community members think about Verona Pharma and other stocks. Vote "Outperform" if you believe VRP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRP will underperform the S&P 500 over the long term. You may vote once every thirty days.
